Phase II, Open-Label Study, to Assess the Long-Term Safety of Oral TMX-67 in Subjects With Gout.
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2015
At a glance
- Drugs Febuxostat (Primary)
- Indications Gout
- Focus Therapeutic Use
- Acronyms FOCUS
- 31 Aug 2018 Biomarkers information updated
- 21 Jul 2009 Sponsor, lead trial centre (Takeda Global Research and Development Center) added as reported by ClinicalTrials.gov.
- 21 Jul 2009 Actual number of patients (116) added as reported by ClinicalTrials.gov.